TRIM13, tripartite motif containing 13, 10206
N. diseases: 275; N. variants: 1
Source: ALL
Disease | Score gda | Association Type | Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
0.070 | GeneticVariation | disease | BEFREE | Targeting Glioblastoma with CAR T Cells. | 28108463 | 2017 | ||||
|
0.070 | GeneticVariation | disease | BEFREE | CSPG4 Shows Promise for Glioblastoma CAR T Therapy. | 29540359 | 2018 | ||||
|
0.070 | Biomarker | disease | BEFREE | These results suggested that tumor-selective, bitargeted anti-EGFR/EGFRvIII CAR T cells may be a promising modality for the treatment of patients with EGFR/EGFRvIII-overexpressing glioblastoma.<i></i>. | 30201736 | 2018 | ||||
|
0.070 | Biomarker | disease | BEFREE | We transduced human NK cell lines NK-92 and NKL, and primary NK cells with a lentiviral construct harboring a second generation CAR targeting both wtEGFR and EGFRvIII and evaluated the anti-GB efficacy of EGFR-CAR-modified NK cells. | 26155832 | 2015 | ||||
|
0.070 | Biomarker | disease | BEFREE | Here, we discuss effects of the GB tumor microenvironment on NK-cell functionality, summarize early treatment attempts with <i>ex vivo</i> activated NK cells, and describe relevant CAR target antigens validated with CAR-T cells. | 31798595 | 2019 | ||||
|
0.070 | Biomarker | disease | BEFREE | A single dose of peripherally infused CAR T cells cleared antigen-expressing tumor cells in patients with glioblastoma, a 10-person trial found. | 28754782 | 2017 | ||||
|
0.070 | Biomarker | disease | BEFREE | A first-in man exploratory study evaluating EGFRvIII-specific CAR T cells for patients with newly diagnosed glioblastoma demonstrated overall safety of CAR T cell therapy and effective target recognition. | 29666934 | 2018 |